This is Everyday Science with Clare Wilson, a subscriber-only newsletter from The i Paper. If you’d like to get this direct to your inbox every week, you can sign up here.
Hello, and welcome back to Everyday Science.
When the NHS rejected two new treatments for Alzheimer’s disease last year on the grounds that they are not cost-effective, medical charities and some doctors branded the decision a blow to patients. But this week, an independent review has found that the drugs don’t deliver any worthwhile benefits.
Why can’t experts agree on whether the drugs work or not – and what are the other options for patients and their families?
Shorts
